IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v33y2015i9p925-937.html
   My bibliography  Save this article

The Economic and Humanistic Burden of Severe Sepsis

Author

Listed:
  • Bogdan Tiru
  • Ernest DiNino
  • Abigail Orenstein
  • Patrick Mailloux
  • Adam Pesaturo
  • Abhinav Gupta
  • William McGee

Abstract

Sepsis and severe sepsis in particular remain a major health problem worldwide. Their cost to society extends well beyond lives lost, as the impact of survivorship is increasingly felt. A review of the medical literature was completed in MEDLINE using the search phrases “severe sepsis” and “septic shock” and the MeSH terms “epidemiology”, “statistics”, “mortality”, “economics”, and “quality of life”. Results were limited to human trials that were published in English from 2002 to 2014. Articles were classified by dominant themes to address epidemiology and outcomes, including quality of life of both patient and family caregivers, as well as societal costs. The severity of sepsis is determined by the number of organ failures and the presence of shock. In most developed countries, severe sepsis and septic shock account for disproportionate mortality and resource utilization. Although mortality rates have decreased, overall mortality continues to increase and is projected to accelerate as people live longer with more chronic illness. Among those who do survive, impaired quality of life, increased dependence, and rehospitalization increase healthcare consumption and, along with increased mortality, all contribute to the humanistic burden of severe sepsis. A large part of the economic burden of severe sepsis occurs after discharge. Initial inpatient costs represent only 30 % of the total cost and are related to severity and length of stay, whereas lost productivity and other indirect medical costs following hospitalization account for the majority of the economic burden of sepsis. Timeliness of treatment as well as avoidance of intensive care unit (ICU)-acquired illness/morbidity lead to important differences in both cost and outcome of treatment for severe sepsis and represent areas where improvement in care is possible. The degree of sophistication of a health system from a national perspective results in significant differences in resource use and outcomes for patients with serious infections. Comprehensive understanding of the cost and humanistic burden of severe sepsis provides an initial practical framework for health policy development and resource use. Copyright Springer International Publishing Switzerland 2015

Suggested Citation

  • Bogdan Tiru & Ernest DiNino & Abigail Orenstein & Patrick Mailloux & Adam Pesaturo & Abhinav Gupta & William McGee, 2015. "The Economic and Humanistic Burden of Severe Sepsis," PharmacoEconomics, Springer, vol. 33(9), pages 925-937, September.
  • Handle: RePEc:spr:pharme:v:33:y:2015:i:9:p:925-937
    DOI: 10.1007/s40273-015-0282-y
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s40273-015-0282-y
    Download Restriction: Access to full text is restricted to subscribers.

    File URL: https://libkey.io/10.1007/s40273-015-0282-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. R S Nannan Panday & T C Minderhoud & D S Chantalou & N Alam & P W B Nanayakkara, 2019. "Health related quality of life in sepsis survivors from the Prehospital Antibiotics Against Sepsis (PHANTASi) trial," PLOS ONE, Public Library of Science, vol. 14(10), pages 1-14, October.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:33:y:2015:i:9:p:925-937. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.